Drug Price Transparency (DPT) Act

On March 6, 2019, Senator Mike Braun (R-IN) introduced the Drug Price Transparency (DPT) Act (S. 657), which would extend the idea of the HHS OIG PBM rebate rule to the commercial insurance market and prohibit PBMs from receiving any rebates or reductions in price from drug manufacturers.